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Recently, methotrexate (MTX) has been used to target to folate (FA) receptor-overexpressing cancer cells for targeted
drug delivery. However, the systematic evaluation of MTX as a Janus-like agent has not been reported before. Here, we
explored the validity of using MTX playing an early-phase cancer-specific targeting ligand cooperated with a late-phase
therapeutic anticancer agent based on the PEGylated chitosan (CS) nanoparticles (NPs) as drug carriers. Some
advantages of these nanoscaled drug delivery systems are as follows: (1) the NPs can ensure minimal premature
release of MTX at off-target site to reduce the side effects to normal tissue; (2) MTX can function as a targeting
ligand at target site prior to cellular uptake; and (3) once internalized by the target cell, the NPs can function as
a prodrug formulation, releasing biologically active MTX inside the cells. The (MTX + PEG)-CS-NPs presented a
sustained/proteases-mediated drug release. More importantly, compared with the PEG-CS-NPs and (FA + PEG)-CS-NPs,
the (MTX + PEG)-CS-NPs showed a greater cellular uptake. Furthermore, the (MTX + PEG)-CS-NPs demonstrated a
superior cytotoxicity compare to the free MTX. Our findings therefore validated that the MTX-loaded PEGylated
CS-NPs can simultaneously target and treat FA receptor-overexpressing cancer cells.
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Nanotechnology is a rapidly advancing and key field of
drug delivery. A great variety of nanoparticle (NP)-based
therapeutic products have entered clinical development
or been approved for clinical use [1]. As an excellent
biocompatible and biodegradable nanomaterial with
low toxicity and immunogenicity, chitosan (CS)-based
nanocarriers presented great advantages for drug, pro-
tein, and gene delivery in therapeutics [2-5]. However,
most CS-based nanocarriers were easily sequestered by
macrophages in the mononuclear phagocyte system
(MPS) after intravenous administration. To avoid the rapid
clearance of the CS-NPs during circulation, PEGylation
can be used to improve the physiological stability, reduce
the opsonization, and increase the possibility reaching the* Correspondence: houzhenqing@xmu.edu.cn; zhangqiq@126.com
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in any medium, provided the original work is ptumor by the enhanced permeation and retention (EPR)
effect (40 to 400 nm) [6-8].
Despite these advantages of the passive targeting, the
main obstacle encountered with the clinical use of the
PEGylated CS-NPs is how to facilitate their internaliza-
tion in the target cells while reducing the unintended
side effects. One strategy is the further functionalization
of the PEGylated CS-NPs with active targeting agents.
For instance, some ligands or antibodies could specifically
recognize the receptors or antigens on the surface of
various cancer cells [9]. Notably, the exploitation of
folate (FA) receptor for targeted drug delivery has long
been persued. FA receptors were overexpressed in a
wide variety of cancer cells, including ovarian, lung,
breast, kidney, and brain cancer cells, but its level is
very low in normal cells [10,11]. Previously, we synthe-
sized the CS-NPs by the combination of ionic gelation
and chemical cross-linking method and prepared the
(FA + PEG)-CS-NPs by dual-conjugation with mPEG-SPA
and FA [12]; the enhanced cellular uptake and tumor
accumulation also inspired our motivation of adoptingOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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extensively used anticancer drug methotrexate (MTX).
MTX, as an analogue of FA for high structural simi-
larity, can enter cells by reduced FA carrier, proton-
coupled FA transporter, or membrane-associated FA
receptor [13-15]. MTX could inhibit dihydrofolate
reductase (DHFR) activity and stop FA cycle, and in
turn inhibit the DNA synthesis and cell proliferation,
and finally drives cells to death [16-18]. Recently,
MTX has been developed to target to FA receptor-
overexpressing cancer cells in vitro [19-21]. These
encouraged the vision and enhanced the scope of
Janus-like MTX as an early-phase cancer-specific target-
ing ligand coordinated with a late-phase therapeutic
anticancer agent with promising potential in vitro and
in vivo. Particularly, Janus role of MTX as a promising
candidate has attracted an increasing interest and may
provide a new concept for drug delivery and cancer
therapy [22-25]. Validation is also a crucial step in the
drug discovery process [26,27]. To prove the validity
and investigate the efficiency of the Janus role on the
nanoscaled drug delivery systems, our present work is
greatly enthused by the Janus-like MTX and we used
the PEGylated CS-NPs to develop the Janus-like
(MTX + PEG)-CS-NPs. Mechanisms of their targeting
and anticancer dual effect were schematically illustrated in
Figure 1.Figure 1 Mechanism of Janus role of the (MTX+ PEG)-CS-NPs. Once intr
were accumulated at the tumor site by the EPR effect. Prior to the cellular
delivery system, in which MTX can function as a targeting moiety and sele
the target cells, the (MTX + PEG)-CS-NPs were served similarly as a prodrug
function as a therapeutic anticancer agent. Additionally, the protease-med
targeting (via FA receptor-mediated endocytosis) to anticancer (inhibit DH
unanticipated targeting coordinated with anticancer efficiency of Janus-likMethods
Materials
All chemical reagents were of analytical grade and used
without further purification unless otherwise stated.
Chitosan (CS, Mw= 70,000 Da, 95% degree of deacetyla-
tion) was purchased from Zhejiang Aoxing Biotechnology
Co., Ltd. (Zhengjiang, China). 1-Ethyl-3-(3-dimethyla-
minopropyl) carbodiimide (EDC), N-hydroxysuccinimide
(NHS), and crude proteases from bovine pancreas were
purchased from Sigma Chemical Corp (St. Louis, MO,
USA). Folate (FA) and methotrexate (MTX) were pur-
chased from Bio Basic Inc. (Markham, Ontario, Canada).
N-Succinimidyl ester of methoxypolyethylene glycol pro-
pionic acid (mPEG-SPA, Mw= 2,000 Da) was purchased
from Jiaxing Biomatrix Inc. (Zhengjiang, China). A dialysis
bag (Mw= 8,000 to 14,000 Da) was ordered from Greenbird
Inc. (Shanghai, China). A Spectra/Por dialysis membrane
(Mw = 6,000 to 8,000 Da) was purchased from Spectrum
Laboratories (Rancho Domingues, CA, USA). Deionized
(DI) water was used throughout. Fetal bovine serum (FBS)
was purchased from Gibco Life Technologies (AG,
Zug, Switzerland). Trypsin-EDTA (0.25%) and penicillin-
streptomycin solution was from Invitrogen. All solvents
used in this study were high-performance liquid chroma-
tography (HPLC) grade. HeLa cells and MC 3 T3-E1 cells
were provided by American Type Culture Collection
(ATCC, Manassas, VA, USA).avenously administrated, it was anticipated that the (MTX + PEG)-CS-NPs
take, the (MTX + PEG)-CS-NPs were served similarly as a targeted drug
ctively transport the NPs to the target cells. Once internalized into
system, in which MTX would be released inside the cells and
iated drug release could ensure that MTX timely change its role from
FR activity and stop FA cycle). This work systematically revealed the
e MTX in vitro.
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Firstly, the CS-NPs were prepared by the ionic gelation
combined with chemical cross-linking method according
to our previous work [12]. Secondly, mPEG-SPA (50 mg)
was added into the CS-NPs suspensions (5 mL, 10 mg/mL)
accompanied by vigorous stirring for 4 h. The prepared
PEG-CS-NPs were dialyzed against DI water to remove
excess of mPEG-SPA using a dialysis bag (Mw= 8,000 to
14,000 Da) and lyophilized for 24 h. Lastly, MTX (5 mg),
EDC (8 mg), and NHS (5 mg) were dissolved in 5 mL of
PBS (pH = 7.4). The pH was adjusted to 6.0 by the
addition of 0.2 M HCl. The mixture was allowed to react
for 30 min and added dropwise to the PEG-CS-NPs
suspension (5 mL, 10 mg/mL). The pH was adjusted to
8.0 with 0.2 M NaOH. The reaction was allowed to
occur at room temperature for 48 h. Following MTX
conjugation, the (MTX + PEG)-CS-NPs NPs were cen-
trifuged at 20,000 rpm for 30 min at 4°C, washed with
PBS/DI water, and lyophilized for 24 h. All of the superna-
tants were collected for further indirect calculation of the
drug-loading content. The (FA + PEG)-CS-NPs were pre-
pared by the same method.
Physicochemical characterization of (MTX + PEG)-CS-NPs
Fourier transform infrared spectroscopy (FTIR) spectrum
analysis of (MTX+ PEG)-CS-NPs was performed using a
NicoletAVTAR36 FTIR Spectrometer (Thermo Scientific,
Salt Lake City, UT, USA). For comparison, The CS-NPs,
PEG, PEG-CS-NPs, and MTX were used as controls.
Average particle size and polydispersity index (PDI)
were determined by dynamic light scattering (DLS) using
a Malvern Zetasizer Nano-ZS (Malvern Instruments,
Worcestershire, UK). Zeta potential was evaluated by
electrophoretic light scattering (ELS) with Zetaplus
(Brookhaven Instruments Corporation, Holtsville, NY,
USA). Particle size was evaluated by intensity distribution.
Atomic force microscopy (AFM) study was performed on
a Nanoscope Multimode atomic force microscope (Veeco
Instruments Inc., New York, USA). Transmission electron
microscopy (TEM) image was obtained on a JEM 2100
transmission electron microscope (JEOL, Tokyo, Japan).
The amount of drug in the supernatant was assayed
using a high-performance liquid chromatography (Waters
Associates, Milford, MA, USA) system with the following
conditions: stationary phase, Hypersill ODS column
(250 mm × 4.6 mm, 5 μm); mobile phase, potassium
dihydrogen phosphate buffer (pH 4.5)-acetonitrile (88:12);
elution flow rate, 1 mL/min; and detection wavelength,
303 nm. The drug-loading content was calculated accord-
ing to the previous report [12].
In vitro stability tests
PBS stability test against ionic strength and plasma stability
test against protein adsorption were evaluated immediatelyafter preparation and subsequently at regular intervals.
Briefly, 5 mg of the lyophilized (MTX+PEG)-CS-NPs were
suspended in PBS (pH 7.4) or 10% (v/v) plasma/heparin
in PBS and stored at 37°C for 120 h. The particle size
was determined at 0, 24, 48, 72, 96, and 120 h, respectively.
In vitro drug release
In vitro release of MTX from the (MTX + PEG)-CS-NPs
was evaluated by a dialysis method. The lyophilized
(MTX + PEG)-CS-NPs suspended in 10% plasma (with
or without the presence of crude proteases) were added
into a dialysis bag (Mw= 6,000 to 8,000 Da) and immersed
into the release medium at 37°C with agitation. At the
predesigned time points, 2 mL of the release medium was
completely withdrawn and subsequently replaced with the
same volume of fresh PBS. For comparison, in vitro
release of the free MTX was evaluated as a control.
Cell culture
HeLa cells were cultured in FA-deficient Dulbecco’s
Modified Eagle’s Medium (DMEM) supplemented with
10% fetal bovine serum (FBS) and 1% penicillin-strepto-
mycin. MC 3 T3-E1 cells were cultured in Minimum
Essential Medium, Alpha Modified (α-MEM), under
similar conditions. The two cell lines have different levels
of FA receptor expression. In particular, HeLa cells (cancer
cells) are FA receptor positive, and MC 3 T3-E1 cells
(normal cells) are FA receptor negative. All of the cells
were cultivated in a 5% CO2-humidified atmosphere at
37°C.
In vitro cellular uptake
To qualitatively investigate the cellular uptake of the
PEG-CS-NPs, (FA + PEG)-CS-NPs or (MTX + PEG)-
CS-NPs, fluorescein isothiocyanate (FITC) was conjugated
to different formulations to prepare the FITC-PEG-CS-
NPs, FITC-(FA + PEG)-CS-NPs or FITC-(MTX + PEG)-
CS-NPs. HeLa cells were seeded at a density of 8 × 104
cells per well into 6-well plates with their specific cell cul-
ture medium. The cells were incubated at 37°C and 5%
CO2 for 24 h. One hundred microliters of the FITC-PEG-
CS-NPs, FITC-(FA + PEG)-CS-NPs, or FITC-(MTX +
PEG)-CS-NPs was added to HeLa cells at the equiva-
lent concentration of FITC and incubated further for
6 h. HeLa cells were washed with PBS and stained with
Hoechst 33258. Then, HeLa cells were washed with
PBS and fixed with 4% formaldehyde. The cells were
observed using a Leica TCS SP5 laser confocal scanning
microscopy (Leica Microsystems, Mannheim, Germany).
To quantitatively investigate the internalization of the
FITC-labeled (MTX+ PEG)-CS-NPs, (FA + PEG)-CS-NPs
or PEG-CS-NPs, HeLa cells were incubated in 6-well
plates at a density of 2 × 105 cells/mL and allowed
to grow for 24 h. The FITC-(MTX + PEG)-CS-NPs,
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the equivalent concentration of FITC were then added to
each well. After incubation for 4 h, the cells were washed
with cold PBS twice, harvested by 0.25% (w/v) trypsin/
0.03% (w/v) EDTA, centrifuged at 1,000 rpm for 5 min at
4°C and resuspended in PBS for the analysis by a Coulter
EPICS XL Flow Cytometer (Beckman Coulter Inc., Brea,
CA, USA).
In vitro cell viability studies
Cytotoxicity of the PEG-CS-NPs, (FA + PEG)-CS-NPs,
(MTX + PEG)-CS-NPs, and free MTX were evaluated by
MTT assay. HeLa cells (cancer cells) or MC 3 T3-E1
cells (normal cells) were seeded at a density of 3 × 103
cells per well into 96-well plates with their specific cell
culture medium. The cells were incubated at 37°C in
humidified atmosphere containing 5% CO2 for 24 h. The
medium was then replaced with fresh medium, and
different formulations were added to incubate with the
cells. After 24 h of incubation, the medium was removed;
each well was rinsed with PBS; and 20 μL of MTT solution
was added followed by incubation for 4 h. Then, the me-
tabolized product MTT formazan was dissolved by adding
200 μL of DMSO to each well. Finally, the plate was
shaken for 20 min, and the absorbance of the formazan
product was measured at 570 nm in a microplate reader
(Bio-Rad, Model 680, Bio-Rad Laboratories, Richmond,
CA, USA).
Subcellular localization
To further understand the mechanisms of in vitro
cell viability studies, we investigated the subcellular
localization using a laser confocal scanning microscopy.
After the predesigned incubation times with the FITC-
labeled (MTX + PEG)-CS-NPs, HeLa cells were washed
with PBS and stained with LysoTracker Red following the
manufacturer’s instructions. The cells were then washed
with PBS, fixed with 4% formaldehyde for 15 min and ob-
served by a laser confocal scanning microscopy.
Results and discussion
Preparation of the (MTX + PEG)-CS-NPs
We used a two-step procedure for the preparation of the
(MTX + PEG)-CS-NPs based on the CS-NPs (Figure 2).
Firstly, the succinimidyl groups of mPEG-SPA were
conjugated to the amino groups of the CS-NPs, as the
PEG-CS-NPs with methoxy surface groups were ideal
for drug delivery [28]. Subsequently, the γ-carboxyl
groups within MTX were conjugated to the residual
amino groups of PEG-CS-NPs via carbodiimide chemistry
[19]. As is reported, FA retained a high affinity for FA re-
ceptor even when conjugated with a wide variety of mole-
cules, thus making it a potential useful tumor-targeting
ligand [10].Thus, it is expected that the conjugation of theMTX molecule with the PEGylated CS-NPs could not
only preserve its accessibility to the FA receptor site to
exert the targeting effect, but concomitantly avoid its pre-
mature release to reduce the side effects of chemotherapy.
Physicochemical characterization of the (MTX + PEG)-CS-NPs
FTIR analysis. The comparative FTIR spectra of all kinds
of NPs were shown in Figure 3. The CS-NPs showed a
broad band at 3,440 cm−1, which was assigned to the
superposition of N-H and O-H stretching vibration of
the polymer backbone of the CS-NPs. Following the
modification of mPEG-SPA, an intensity increase was
observed in the alkyl C-H stretching vibration at
2,887 cm−1. The peaks at 1,728 and 1,114 cm−1 indicated
the C =O and C-O-C stretching vibration native to the
structure of mPEG-SPA, respectively. These results
testified to the successful PEGylation. After the further
modification of MTX, the peak at 1,713 cm−1 indicated
the generation of new C = O stretching vibration, more
importantly, the appearance of the peaks at 1,652 and
1,564 cm−1 were indicative of the introduction of a
greater conjugated system; in other words, the results
suggested that the interaction between PEG-CS-NPs
and MTX was at the level of a new amide bond.
Particle size, PDI, zeta potential, and morphology. Sur-
face biofunctionalization was accompanied by the changes
in particle size (Figure 4A) and zeta potential (Figure 4B)
of the NPs. After PEGylation and MTX modification, the
particle size increased from 190.1 to 213.4 nm, and the
zeta potential decreased from 45.7 to 39.6 mV, and then
increased to 47.9 mV. Particle size of approximately
200 nm was suited for the prolonged circulation because
they were big enough to avoid the rapid uptake by the
RES but small enough to avoid the rapid renal clearance
[7,29]. The best EPR effect for a rigid particle is achieved
for particle size <400 nm [6,30]. Surface charge is an
important indication for the stability of the nanoscaled
drug delivery system in the physiological environment.
The electrostatic repulsion among the NPs with the same
type of surface charge would confer stability [31,32].
The (MTX + PEG)-CS-NPs presented a spherical shape
(Figure 4C), a nanoscaled particle size (Figure 4D), a
narrow particle size distribution (Figure 4D), a high zeta
potential (Figure 4E), a moderate drug-loading content
(7.23 ± 0.11%, discussed below), and a good physiological
stability (see Figure 4F,G, discussed below), indicating that
they were effective therapeutic drug delivery systems [1].
Drug-loading content. CS-NPs possessing peripheral
amino groups provided us great opportunities to easy
surface biofunctionalization. In our study, the γ-carboxyl
groups of MTX were conjugated to the residual amino
groups of the PEGylated CS-NPs. The drug-loading
content of the (MTX + PEG)-CS-NPs was calculated as
7.23 ± 0.11%. The simple conjugation chemistry and
Figure 2 Synthetic scheme of the (MTX + PEG)-CS-NPs.
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acting role of Janus-like MTX.
In vitro stability tests
No significant variation of the particle size was observed
in the (MTX + PEG)-CS-NPs even after incubation with
PBS for a long period of time (Figure 4F). Notably, the
CS-NPs (without PEGylation) could precipitate after 48 hin the presence of salts. It was implied that PEG could
protect the (MTX+ PEG)-CS-NP against ionic strength.
No significant change of the particle size was also shown
in the (MTX + PEG)-CS-NPs after incubation with
10% plasma for 120 h (Figure 4G). It should be in-
ferred that PEG could reduce the plasma proteins ad-
sorption, and more importantly, preserve the targeting
potential of MTX. All of the results suggested that the
Figure 3 FTIR spectra of the (A) CS-NPs, (B) PEG, (C) PEG-CS-NPs, (D) MTX, and (E) (MTX + PEG)-CS-NPs.
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physiological conditions for extended blood circulation.
In vitro drug release profiles
In vitro drug release profiles of the free MTX and
(MTX + PEG)-CS-NPs were presented in Figure 5. To
mimic the physiological conditions of the bloodstream,
the (MTX + PEG)-CS-NPs were incubated with 10%
plasma at pH 7.4. In sharp contrast to the free MTX
with accumulated release amounts of almost 90% within
6 h, a more sustained release of the NPs was clearly
observed due to the slow hydrolysis of amide bonds.
Nevertheless, within 48 h, only no more than 10% of
MTX from NPs was released at pH 7.4. Once intraven-
ously administrated, the NPs could ensure minimal
premature release of MTX during the circulation, and
thereby greatly reduces the systemic toxicity. It was ex-
pected that the NPs will accumulate at the tumor site
by the EPR effect. Once inside the tumor tissue, these
MTX-targeted PEG-CS-NPs will be internalized by the
tumor cells, largely via FA receptor-mediated endocytosis
(discussed below).
It was well established that the amide bonds could be
selectively cleaved at acidic pH by proteases (also calledproteolytic enzymes) overexpressed in the tumor cells
[33-36]. To simulate the physiological environment of
the acidic compartments of the tumor cells, the (MTX +
PEG)-CS-NPs were incubated with 10% plasma contain-
ing crude proteases at pH 5.0. MTX was released at a con-
stant rate up to 10 h, reaching the accumulated release
amounts more than 30%, we believed that proteases
exerted a significant promotion effect to control drug re-
lease. As is reported, several kinds of particle-bound MTX
attached by an amide linkage have been shown to be
sensitive to the protease-mediated cleavage in the acidic
environments, and hence, the lysosomal proteases could
be responsible for the release of MTX from the particles
[19,20,37,38]. Once the NPs were internalized by the
target cells, the drug release could be significantly speeded
up because of the long-lasting activity of proteases inside
the cells, which can help to provide a sufficient intracellu-
lar level of MTX, and hence efficiently enhance the drug
efficacy.
All of the results suggested that the covalent chemistry,
preferring over physical adsorption, could be advanta-
geous to preserve the targeting role of MTX. This could
be of utmost importance, especially in vivo, where the
avoidance of premature drug release and the untimely role
Figure 4 Physicochemical characterization of the (MTX + PEG)-CS-NPs. (A) Particle size of the CS-NPs, PEG-CS-NPs, and (MTX + PEG)-CS-NPs
(mean ± SD, n= 3). (B) Zeta potential of the CS-NPs, PEG-CS-NPs, and (MTX + PEG)-CS-NPs (mean ± SD, n= 3). (C) AFM image of the (MTX + PEG)-CS-NPs.
Scale bars = 500 nm. Inset: TEM image of the (MTX + PEG)-CS-NPs. Scale bars = 50 nm. (D) Particle size distribution of the (MTX + PEG)-CS-NPs. (E) Zeta
potential distribution of the (MTX+ PEG)-CS-NPs. (F) In vitro stability tests of the (MTX + PEG)-CS-NPs in PBS (mean ± SD, n= 3). (G) In vitro stability tests of
the (MTX + PEG)-CS-NPs in 10% plasma in PBS (mean ± SD, n= 3).
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Figure 5 In vitro drug release profiles of the (MTX + PEG)-CS-NPs in different physiological media (mean ± SD, n = 3).
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are pivotal.
In vitro cellular uptake
We investigated the comparative cellular uptake of dif-
ferent formulations by HeLa cells using laser scanning
confocal microscopy (Figure 6). The FA modification en-
hanced the cellular uptake of the FITC-(FA + PEG)-CS-
NPs compared with the FITC-PEG-CS-NPs (Figure 6A,B).
These results can be explained by their distinct cellular
uptake mechanisms. The FITC-PEG-CS-NPs might be
taken up by the cells through nonspecific endocytosis,
while the FA receptor-mediated endocytosis could further
promote the cellular uptake of the FITC-(FA + PEG)-CS-
NPs. More importantly, it was of interest to note that the
MTX modification also significantly enhanced the cellular
uptake of the FITC-(MTX + PEG)-CS-NPs (Figure 6C),
indicating that MTX greatly improved the targeting effect.
To evaluate the specificity of the cellular uptake of the
FITC-(MTX+ PEG)-CS-NPs, FA competition experiments
were carried out. The internalization of the FITC-(MTX+
PEG)-CS-NPs by the free FA-treated HeLa cells was greatly
inhibited compared to the untreated HeLa cells (Figure 6D);
these results suggested that the MTX functionalized
nanoscaled drug delivery systems could specifically bind
to FA receptor. But, equally important is that another pos-
sibility should not be neglected. Despite that, MTX has a
suboptimal affinity for FA receptor compared with FA
[13]; the multiple MTX ligands decorated on the (MTX+
PEG)-CS-NPs can be bound simultaneously to multipleFA receptors overexpressed on the surface of cancer cells
and promote the multivalent binding effect [39,40], which
resulted in the collectively much tighter binding avidity
[41,42] and progressively more efficient drug delivery
through FA receptor-mediated internalization pathways
that helped circumvent multiple-drug resistance (MDR)
efflux mechanisms [43].
We next made quantitative measurements of the cellu-
lar uptake of different PEG-CS-NPs formulations using
flow cytometry. The mean fluorescence intensities (MFIs)
of the cells after 4 h of incubation with different PEG-
CS-NPs formulations were shown in Figure 7. The MFI
should be directly correlated with the mean number of
NPs taken up per cell. The MFI of HeLa cells treated
with the FITC-(FA + PEG)-CS-NPs was significantly
higher than the FITC-PEG-CS-NPs, and even the MFI of
HeLa cells treated with the FITC-(MTX + PEG)-CS-NPs
was also significantly higher than the FITC-(FA + PEG)-
CS-NPs. These results also supported the idea of the tar-
geting effect of both the FITC-(FA + PEG)-CS-NPs and
FITC-(MTX+ PEG)-CS-NPs to HeLa cells. The presence
of excess of the free FA efficiently inhibited the cellular
uptake of FITC-(MTX+ PEG)-CS-NPs, which confirmed
that the (MTX+ PEG)-CS-NPs enter the cells through the
FA receptor-mediated endocytosis.
These quantitative results were consistent with those
qualitative results, giving a further proof of high targeting
efficacy of the (MTX + PEG)-CS-NPs to HeLa cells. The
possible reason is that the integral binding avidity of the
(MTX+ PEG)-CS-NPs towards FA receptor presents a
Figure 6 In vitro cellular uptake of the (MTX + PEG)-CS-NPs. Laser scanning confocal microscopy images of (A) HeLa cells incubated with the
FITC-PEG-CS-NPs. (B) HeLa cells incubated with the FITC-(FA + PEG)-CS-NPs. (C) HeLa cells incubated with the FITC-(MTX + PEG)-CS-NPs. (D) HeLa
cells blocked with excess of the free FA and then incubated with the FITC-(MTX + PEG)-CS-NPs. Incubation was carried out at 37°C for 6 h. The
concentration of FITC was equivalent in all formulations. All images were taken using identical instrumental conditions and presented at the same
intensity scale.
Figure 7 Cellular uptake of FITC-PEG-CS-NPs, FITC-(FA + PEG)-
CS-NPs, and FITC-(MTX + PEG)-CS-NPs (equivalent FITC
concentration) on HeLa cells by flow cytometry (mean ± SD,
n = 3). Statistical significance: *P <0.05.
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of the (FA + PEG)-CS-NPs towards FA receptor. As
mentioned above, MTX has a suboptimal affinity to FA
receptor compared with FA and may be less efficient to
target to FA receptor than FA. Nevertheless, it was
reported that multivalent binding avidity can be kinetic-
ally limited if the binding affinity of an individual
receptor-ligand pair is too tight [44,45]. Well consistent
with the above theoretical analysis, our result further
suggested that the targeting specificity of the nanoscaled
drug delivery systems for a particular cell type can be
enhanced by the weaker binding affinity of each individ-
ual receptor-ligand pair. Indeed, the integral binding
avidity plays a predominant role in the targeting effi-
cacy; the higher integral binding avidity increases the
targeting efficacy. Detailed in vivo targeting studies are
necessary to further assess this possibility.
Figure 8 (See legend on next page.)
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Figure 8 In vitro cell viability and intracellular delivery. (A) Cytotoxicity of the PEG-CS-NPs, (FA + PEG)-CS-NPs, (MTX + PEG)-CS-NPs, and free
MTX against HeLa cells after 24 h of incubation (mean ± SD, n = 6). Statistical significance: *P < 0.05. (B) Cytotoxicity of the PEG-CS-NPs,
(FA + PEG)-CS-NPs, (MTX + PEG)-CS-NPs, and free MTX at the highest MTX concentration (10 μg/mL) against HeLa cells (cancer cells) or MC 3 T3-E1 cell
(normal cells) after 24 h of incubation (mean ± SD, n = 6). Statistical significance: *P < 0.05. (C) Intracellular delivery of the (MTX + PEG)-CS-NPs in HeLa
cells after 4 h of incubation observed by laser scanning confocal microscopy. The late endosomes and lysosomes were stained by LysoTracker Red.
(a) Green fluorescent FITC, (b) red fluorescent late endosomes/lysosomes, (c) overlay of (a) and (b).
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The cytotoxicities of the PEG-CS-NPs, (FA + PEG)-CS-
NPs, (MTX + PEG)-CS-NPs, and free MTX were assessed
by MTT assays after incubation with HeLa cells for 24 h
(Figure 8A). No visible cytotoxic effect of the PEG-CS-
NPs was observed for HeLa cells, and the FA modification
did not significantly alter the cytotoxic effect. In contrast,
both the (MTX + PEG)-CS-NPs and free MTX exhibited
a concentration-dependent cytotoxic effect towards
HeLa cells. Moreover, delivering MTX by the (MTX +
PEG)-CS-NPs significantly induced a much higher cyto-
toxicity compared to delivering the free MTX at the
same drug concentration, even though this cell line is
not MTX resistant. The result can be explained by the
highly specific targeting efficiency, effectively sustained
drug release, and efficient cytotoxicity enhancement
effect of the MTX-targeted nanoscaled drug delivery
systems, which lead to the enhanced cellular accumulation
and retention of MTX.
The cytotoxicity of the (MTX+PEG)-CS-NPs (10 μg/mL)
towards HeLa cells and MC 3 T3-E1 cells after 24 h of
incubation was shown in Figure 8B. FA receptors were
expressed at a high level on the surface of HeLa cells
(cancer cells) but at a much lower level on MC 3 T3-E1
cells (normal cells). On the one hand, the cytotoxicity of
the (MTX + PEG)-CS-NPs towards cancer cells was sig-
nificantly higher compared to that of the free MTX.
However, in the case of normal cells, the situation was
opposite. On the other hand, the (MTX + PEG)-CS-NPs
induced a marked cytotoxicity towards targeted cancer
cells, but a slight cytotoxicity was observed for nontar-
geted normal cells, whereas the free drug affected both
cell lines equally. The result indicated that the MTX
modification played an important role in selectively
enhanced cytotoxicity of the nanoscaled drug delivery
systems [46]. All of these results also suggested that MTX
was not prematurely released from the (MTX + PEG)-CS-
NPs outside of HeLa cell, but was preferentially released
inside HeLa cell after the cellular uptake of the (MTX+
PEG)-CS-NPs.
To investigate the intrinsical mechanisms of the
cytotoxicity of the (MTX + PEG)-CS-NPs, we investi-
gated the subcellular localization of the FITC-labeled
(MTX + PEG)-CS-NPs in HeLa cells by laser scanning
confocal microscopy. As shown in Figure 8C, the inter-
nalized (MTX + PEG)-CS-NPs were found initially tobe localized in the lysosomes, as evidenced by the yellow
spots in the merged image obtained from the images of
the (MTX + PEG)-CS-NPs (green) and late endosomes/
lysosomes (red). The result indicated that the (MTX +
PEG)-CS-NPs were internalized via the endocytosis
pathway into the late endosomes/lysosome [47]. Indeed,
after incubation for 4 h, some green fluorescent FITC-
labeled (MTX + PEG)-CS-NPs were no longer located in
the red fluorescent late endosomes/lysosomes, indicat-
ing the successful endo/lysosomal escape. In agreement
with other reports [37,48], these results combined with
the results of in vitro drug release and cell viability
studies further proved that MTX was released from the
(MTX + PEG)-CS-NPs inside the cells by the intracel-
lular protease-mediated selective cleavage of peptide
bond. These findings were also in agreement with other
reports in the literature [49] that CS possessed the activity
to some extent to escape the endo/lysosome.
Conclusions
We presented the versatile, robust, and easy MTX-based
PEGylated CS-NPs while validating MTX as a successful
targeting ligand coordinated with a simple anticancer
drug, and established the (MTX+ PEG)-CS-NPs as a cock-
tail platform of specific targeting cooperated with enhanced
anticancer activity. MTX was not prematurely released at
off-target site but was intensively released at target site due
to its sustained/protease-mediated drug release characteris-
tic. To the best of our knowledge, the work for the first
time explored the validation of Janus role of MTX based on
the nanoscaled drug delivery system in vitro. Additionally,
as MTX (a targeting ligand/a first drug) was introduced
into one kind of drug carriers, one further advantage was
that the drug delivery systems allowed the further introduc-
tion of a second ligand or a second drug for synergistic
co-targeted delivery or synergistic co-delivery of drugs.
Nevertheless, more details about in vivo targeting and
anticancer investigations are indispensable to obtain a bet-
ter understanding of the therapeutic effect of the (MTX+
PEG)-CS-NPs, and relevant studies are in process.
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